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Artemisinin based combination therapies (ACTs) are
the corner stone of current efforts aimed at the
management and control of  malaria globally.1 In 2004,
Nigeria adopted the recommendation of  the World
Health Organization and made two ACTs (artemether-
lumfanthrine and artesunate Amodiaquine) the first line
malaria therapies. Several studies have confirmed the
high efficacies of  these therapies.2 However, in 2009,
resistance to Artemisin was reported from South-east
Asia.3 Since then, fears of resistance to artemisinin in
sub-saharan Africa have been entertained. Recent
publications from workers in Nigeria are pointing
towards a decline in malaria parasite susceptibility to
artemisinin-based combination therapies.4 These
reports are worrisome and there is a need for
interventions and methods that will delay the
development of artemisinin resistance in the sub region.
This letter describes an observation that suggests the
need for prolonged follow up of malaria patients after
treatment with artemisinin-based therapies in order to
monitor properly the pattern of  recrudescence to ACT
therapies. The following report will contribute to
background data and the need for prolonging the
follow up period in antimalarial studies that may be
essential to the monitoring of recent trends to
artemisinin-based therapies in Nigeria.
In a study conducted at the University College Hospital,
Ibadan, in Southwest Nigeria in 2004, one hundred
and ten (110) children aged below 12 years (mean age
5.9 ± 2.9 years with acute uncomplicated malaria
received Artesunate-Mefloquine (AMq) and were
followed up for 42 days. The study was approved by
the Institutional Ethics Review Board and all
participants gave written informed consent. The
follow-up schedule included blood smears for
microscopy and Polymerase Chain Reaction (PCR) for
genotyping of parasites on days 1, 2, 3, 7, 14, 21, 28,
35, and 42. Enrolled children had parasitemia of 2000/
uL or greater. The children were treated with a
standard dose of Artesunate (4mg/kg) and Mefloquine
(25mg/kg) combination for three days. Drugs were
administered orally. Parasite clearance time in days
before parasite cleared from the peripheral blood film
was determined. Parasite genomic DNA was extracted
from blood samples collected on filter paper using
the Chelex extraction method according to the method
described by Plowe et al 1995.5 In the study,
polymorphism in block 3 of merozoite surface protein
2 (MSP2) in P. falciparum isolates was used for parasite
genotyping. Analyses of  treatment outcome (re-
infection vs. recrudescence) was carried out using
parasite MSP2 loci that exhibited repeat numbers of
polymorphisms to detect the complexity of infection
in individual patient isolate as well as distinguish true
treatment failure (recrudescence) from new infection
(re-infection).
The results showed that the geometric mean parasite
density was 85,089 parasites/µL, parasite clearance
time was 1.4 ± 0.5 days and parasite reduction ratio
was 75.4 x 103 per day for the children studied. During
the course of follow-up children remained without
patent parasitemia until day 21 at which time nine late
treatment failures occurred as shown in the table.
Analysis of parasite genotypes showed that five of
the late treatment failures were recrudescence, while
four were re-infections. There was no occurrence of
mixed re-infection and recrudescence in any of the
children that failed therapy.
The occurrence of late parasite recrudescence was
unexpected at the time the study was carried out. At
that time, there was a general tendency to attribute
parasite re-infections to late treatment failures and
recrudescence to treatment failure before day 14 of
antimalarial therapy. At about the same period, studies
starts showing that distinguishing re-infection and
recrudescence was better done by molecular
differentiation and not by attributing late treatment
failures to re-infection and early treatment failures to
recrudescent parasites.6 In light of  recent decline in
susceptibility to ACTs in Nigeria4 it has become
imperative suggest compliance to a follow up period
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of 42 days minimum and mandatory molecular
differentiation of parasite recrudescence and re-
infection in all antimalarial studies. The relevance of
longer durations of follow up in the setting of current
malaria drug trials have been described in a few
studies7, however studies are still being conducted in
the sub-region and globally with follow up periods
of 28 days, many times on account of financial
implications and participants’ inability to completing
the study.
Ensuring a follow up period of a minimum of 42
days (the longer the duration of follow up the more
advantageous in the case of monitoring for
recrudescent parasites) will enable proper
documentation of local trends in recrudescence to
antimalarial treatment so as to determine appropriate
therapies that will rapidly eliminate parasite
recrudescence and clear recrudescent parasites from
the blood of  infected patients. The usual 28 day follow-
up period should be discouraged and molecular
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012 6.00 4,477 1 27 36 LTF RECRUD
O35 2.83 61,330 2 35 26,636 LTF REINF
048 8.00 16,374 1 42 8,041 LTF REINF
054 6.00 9,877 3 42 58,970 LTF RECRUD
064 7.00 18,870 2 28 8,067 LTF RECRUD
073 4.00 42,000 2 35 1,000 LTF RECRUD
084 11.00 24,000 2 42 120 LTF REINF
100 9.00 227,272 1 21 13,980 LTF RECRUD
110 6.00 116,279 1 42 12,005 LTF REINF
Table: Parasitological characteristics of  the nine patients that failed therapy
Legend: PCT = parasite clearance time in days, RECRUD = Recrudescence, REINF = Reinfection
differentiation between parasite recrudescence and re-
infection be made mandatory. The development of
rapid point of care immunochromatographic tests to
differentiate between malaria parasites recrudescence
and re-infection will significantly support interventions
aimed at delaying the emergence of artemisinin
resistance in Nigeria and the sub-region. Undetected
recrudescence in the community will encourage the
spread of parasites with decreased susceptibility to
artemisinin therapies.
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